News & Insights
Peer-credible reporting on peptide science, regulation, and the research community. No hype. No therapeutic claims.
FDA's 2025 Crackdown on Compounded GLP-1s: What It Means for Research Access
As the agency restores brand-name semaglutide and tirzepatide to its supply list, compounding pharmacies face new constraints — and researchers brace for downstream effects.
New Meta-Analysis Confirms BPC-157's Tissue Healing Mechanism
A pooled review of 47 preclinical studies finds consistent evidence for VEGF-mediated angiogenesis as the central pathway — but human data remains conspicuously absent.
The Rise of Peptide-Based Longevity Protocols Among Caribbean Biohackers
From Barbados to Curaçao, small networks of self-experimenters are running rigorous, well-documented protocols — and producing data the academic world is starting to notice.
Reading Between the Lines: How to Spot a Fake COA
Certificates of Analysis are the foundation of trust in research peptide supply. Here's how to read one properly — and what red flags should make you walk away.
Why Cold Chain Failure Is the Silent Killer of Peptide Quality
A peptide can leave the lab at 99.7% purity and arrive degraded — and the COA on the box will tell you nothing about it. Here's the science of why.
Epitalon and Telomere Research: Where the Science Actually Stands
The synthetic tetrapeptide has been studied for nearly 40 years. Here's what the evidence supports — and what it conspicuously does not.
